Precision Neuro-Clinical Suite
Polypharmacy multi-drug risk matrices, shortest biological path tracing, and pharmacokinetic half-life simulation.
Polypharmacy Multi-Drug Regimen Interaction Matrix (N × N)
Evaluates combined metabolic and pharmacodynamic risk interactions across multi-drug regimens.
| Drug Matrix | Tramadol | Methylphenidate | Fluoxetine | Clonidine |
|---|---|---|---|---|
| Tramadol | Monotherapy | HIGH Tramadol + Methylphenidate HIGH RISK: Additive reduction of seizure threshold and CNS stimulation. | HIGH Tramadol + Fluoxetine HIGH RISK: Serotonin Syndrome & CYP2D6 inhibition reducing Tramadol active metabolite conversion. | LOW Tramadol + Clonidine No severe major cytochrome interaction documented. |
| Methylphenidate | HIGH Methylphenidate + Tramadol HIGH RISK: Additive reduction of seizure threshold and CNS stimulation. | Monotherapy | MODERATE Methylphenidate + Fluoxetine MODERATE: Fluoxetine inhibits CYP2D6, increasing Methylphenidate plasma exposure. | MODERATE Methylphenidate + Clonidine MODERATE: Opposing hemodynamic actions (Alpha-2 agonist vs. Norepinephrine reuptake inhibitor). |
| Fluoxetine | HIGH Fluoxetine + Tramadol HIGH RISK: Serotonin Syndrome & CYP2D6 inhibition reducing Tramadol active metabolite conversion. | MODERATE Fluoxetine + Methylphenidate MODERATE: Fluoxetine inhibits CYP2D6, increasing Methylphenidate plasma exposure. | Monotherapy | LOW Fluoxetine + Clonidine No severe major cytochrome interaction documented. |
| Clonidine | LOW Clonidine + Tramadol No severe major cytochrome interaction documented. | MODERATE Clonidine + Methylphenidate MODERATE: Opposing hemodynamic actions (Alpha-2 agonist vs. Norepinephrine reuptake inhibitor). | LOW Clonidine + Fluoxetine No severe major cytochrome interaction documented. | Monotherapy |
Hover over any matrix cell above to view detailed pharmacodynamic risk analysis and metabolic pathway notes.